Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OMGA Stock Forecast 2025-2026
$0.04
Current Price
$7.90M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to OMGA Price Targets
+32,332.4%
To High Target of $12.00
+30,981.1%
To Median Target of $11.50
+29,629.7%
To Low Target of $11.00
OMGA Price Momentum
+33.3%
1 Week Change
0.0%
1 Month Change
-98.0%
1 Year Change
-94.7%
Year-to-Date Change
-98.6%
From 52W High of $2.63
+270.0%
From 52W Low of $0.01
📊 TOP ANALYST CALLS
Did OMGA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Omega is one of their latest high-conviction picks.
Latest OMGA Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, OMGA has a bullish consensus with a median price target of $11.50 (ranging from $11.00 to $12.00). Currently trading at $0.04, the median forecast implies a 30,981.1% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Robert Burns at HC Wainwright & Co., projecting a 32,332.4% upside. Conversely, the most conservative target is provided by Robert Burns at HC Wainwright & Co., suggesting a 29,629.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OMGA Analyst Ratings
3
Buy
0
Hold
0
Sell
OMGA Price Target Range
Low
$11.00
Average
$11.50
High
$12.00
Current: $0.04
Latest OMGA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OMGA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 15, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $4.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $12.00 |
| Aug 7, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $12.00 |
| Aug 7, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $6.00 |
| Jun 18, 2024 | Raymond James | Ryan Deschner | Outperform | Initiates | $12.00 |
| May 13, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $12.00 |
| May 7, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $7.00 |
| Apr 30, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $12.00 |
| Apr 3, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $9.00 |
| Apr 1, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $7.00 |
| Jan 4, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $12.00 |
| Nov 13, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $12.00 |
| Nov 10, 2023 | Wedbush | Robert Driscoll | Outperform | Maintains | $12.00 |
| Sep 1, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $11.00 |
| Aug 4, 2023 | Chardan Capital | Buy | Reiterates | $0.00 | |
| Jun 6, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $11.00 |
| May 8, 2023 | Chardan Capital | Keay Nakae | Buy | Reiterates | $12.00 |
| Mar 31, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $11.00 |
| Mar 24, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $11.00 |
| Mar 10, 2023 | JonesTrading | Catherine Novack | Buy | Initiates | $11.00 |
Omega Therapeutics Inc. (OMGA) Competitors
The following stocks are similar to Omega based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Omega Therapeutics Inc. (OMGA) Financial Data
Omega Therapeutics Inc. has a market capitalization of $7.90M with a P/E ratio of 0.0x. The company generates $8.10M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +214.3% quarter-over-quarter, while maintaining an operating margin of -628.6% and return on equity of -166.9%.
Valuation Metrics
Market Cap
$7.90M
Enterprise Value
$105.65M
P/E Ratio
0.0x
PEG Ratio
-0.2x
Price/Sales
1.0x
Growth & Margins
Revenue Growth (YoY)
+214.3%
Gross Margin
N/A
Operating Margin
-628.6%
Net Margin
0.0%
EPS Growth
+214.3%
Financial Health
Cash/Price Ratio
+1,483.8%
Current Ratio
1.6x
Debt/Equity
1,110.0x
ROE
-166.9%
ROA
-25.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Omega Therapeutics Inc. (OMGA) Business Model
About Omega Therapeutics Inc.
What They Do
Develops innovative epigenomic therapeutics for diseases.
Business Model
Omega Therapeutics generates revenue by developing and commercializing epigenetic therapies aimed at treating genetic disorders, oncology, and other medical fields. Its proprietary platform, Omega Dev, enables precise modulation of gene expression, positioning the company within the growing personalized medicine market.
Additional Information
Headquartered in Cambridge, Massachusetts, Omega Therapeutics benefits from its location in a prominent biotech hub, facilitating collaborations and access to essential resources. The company's focus on addressing unmet medical needs highlights its potential impact in the biotechnology industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
93
CEO
Dr. Kaan Certel Ph.D.
Country
United States
IPO Year
2021
Website
omegatherapeutics.comOmega Therapeutics Inc. (OMGA) Latest News & Analysis
Latest News
Quick Summary
Omega Therapeutics, Inc. (OMGA) reported a quarterly loss of $0.30 per share, slightly exceeding the estimate of $0.29, and improved from a loss of $0.40 per share a year prior.
Why It Matters
Omega Therapeutics' quarterly loss exceeded expectations, indicating potential operational challenges. However, the reduced loss from the previous year may signal improving performance, influencing investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Omega Therapeutics (Nasdaq: OMGA) will present new preclinical data at three scientific meetings, highlighting its innovative epigenomic mRNA medicines.
Why It Matters
Omega Therapeutics' announcement of new preclinical data may signal advancements in their mRNA technology, potentially impacting stock performance and investor sentiment in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
8 months ago
Quick Summary
Omega Therapeutics published preclinical data on OTX-2002 in Nature Communications, demonstrating its potential to regulate the MYC gene in liver cancer models, enhancing their epigenomic medicine approach.
Why It Matters
Omega Therapeutics' publication on OTX-2002 showcases its innovative approach to treating liver cancer, potentially attracting investors seeking groundbreaking biotech advancements.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research
10 months ago
Quick Summary
Omega Therapeutics has appointed Dr. Jennifer Nelson as Senior VP of Research. She has 20+ years of experience in RNA and DNA therapies, enhancing the company's leadership in epigenomic mRNA medicines.
Why It Matters
The appointment of Jennifer Nelson strengthens Omega Therapeutics' leadership, enhancing its potential in innovative mRNA therapies, which could improve market confidence and drive stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
10 months ago
Quick Summary
Omega Therapeutics (Nasdaq: OMGA) reported its Q2 2024 financial results and provided updates on its development of programmable epigenomic mRNA medicines.
Why It Matters
Omega Therapeutics' Q2 financial results and progress in developing innovative mRNA therapies indicate potential growth and investment opportunities in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Omega Therapeutics (OMGA) reported a quarterly loss of $0.30 per share, beating the Zacks Consensus Estimate of a $0.36 loss, and improving from a loss of $0.54 per share a year prior.
Why It Matters
Omega Therapeutics' smaller-than-expected quarterly loss signals improving financial performance, potentially boosting investor confidence and stock value.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About OMGA Stock
What is Omega Therapeutics Inc.'s (OMGA) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Omega Therapeutics Inc. (OMGA) has a median price target of $11.50. The highest price target is $12.00 and the lowest is $11.00.
Is OMGA stock a good investment in 2025?
According to current analyst ratings, OMGA has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OMGA stock?
Wall Street analysts predict OMGA stock could reach $11.50 in the next 12 months. This represents a 30,981.1% increase from the current price of $0.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Omega Therapeutics Inc.'s business model?
Omega Therapeutics generates revenue by developing and commercializing epigenetic therapies aimed at treating genetic disorders, oncology, and other medical fields. Its proprietary platform, Omega Dev, enables precise modulation of gene expression, positioning the company within the growing personalized medicine market.
What is the highest forecasted price for OMGA Omega Therapeutics Inc.?
The highest price target for OMGA is $12.00 from Robert Burns at HC Wainwright & Co., which represents a 32,332.4% increase from the current price of $0.04.
What is the lowest forecasted price for OMGA Omega Therapeutics Inc.?
The lowest price target for OMGA is $11.00 from Robert Burns at HC Wainwright & Co., which represents a 29,629.7% increase from the current price of $0.04.
What is the overall OMGA consensus from analysts for Omega Therapeutics Inc.?
The overall analyst consensus for OMGA is bullish. Out of 8 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $11.50.
How accurate are OMGA stock price projections?
Stock price projections, including those for Omega Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2025 4:26 AM UTC